Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U29 (CD30 CAR-T) in CD30-positive Relapsed or Refractory Lymphoma
NCT07453446Phase 1Withdrawn
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of U29 in lymphoma, sponsored by Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 28 days, Treatment-Emergent Adverse Events at 24 months and 4 more. Planned start Mar 2025; status: withdrawn.
02
Drugs
U29
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT07453446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07453446.